Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral.
The posterior maxilla has traditionally been one of the most difficult areas to successfully place dental implants due to poor bone quality and close approximation to the maxillary sinus. Sinus augmentation procedures have become a viable means of assuring adequate bone for the placement of dental implants in this area. However, with the techniques currently employed, a considerable variation in the quality of bone attained with the sinus augmentation procedure exists. The purpose of this in vivo study was to evaluate the healing response and bone formation stimulated by 3 doses of recombinant human osteogenic protein-1 (rhOP-1), 0.25, 0.6, and 2.5 mg OP-1 per gram of collagen matrix; natural bone mineral; or collagen matrix alone (control) placed in the maxillary sinus of adult chimpanzees. Results were assessed using clinical, histologic, and radiographic techniques. Radiographic analysis of the computed tomography scans taken at 1 week, and 2.5, 4.5, and 6.5 months revealed a more rapid mineralization with the 2.5 mg OP-1/g collagen matrix and natural bone mineral treatment groups. The incremental bone mineral density (BMD) increase for these 2 treatments from 1 week to 2.5 months was over 2.5 times the increase found with the collagen matrix alone; these 2 treatments also had a higher BMD at the most superior slices evaluated when compared to the other 3 groups. Biopsy specimens were taken at 3.5, 5.5, and 7.5 months and for all 5 treatment groups bone formation was observed at all time points in the majority of the specimens. At 7.5 months the 2.5 and 0.6 mg OP-1/g collagen matrix treatment groups had an increase in the percent bone area when compared to the matrix alone control. In conclusion, these results demonstrate that sinus augmentation with natural bone mineral or 2.5 mg OP-1/g collagen matrix induce comparable radiographic and histologic evidence of bone formation and that both of these treatments performed superior to the control group of collagen matrix alone based upon all methods of evaluation.
Margolin
M D
MD
Department of Periodontology, Oregon Health Sciences University, Portland, USA.
Cogan
A G
AG
Taylor
M
M
Buck
D
D
McAllister
T N
TN
Toth
C
C
McAllister
B S
BS
D000704:Analysis of Variance; D000818:Animals; D001706:Biopsy; D015519:Bone Density; D001857:Bone Matrix / Q000637:transplantation; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002113:Calcification, Physiologic; D003094:Collagen / Q000627:therapeutic use; D003758:Dental Implantation, Endosseous; D015921:Dental Implants; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D008443:Maxillary Sinus / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D008903:Minerals / Q000627:therapeutic use*; D010012:Osteogenesis; D002679:Pan troglodytes; D011994:Recombinant Proteins; D014057:Tomography, X-Ray Computed; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use*; D014945:Wound Healing
C525819:BMP7 protein, human; C077540:Bio-Oss; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D015921:Dental Implants; D008903:Minerals; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D003094:Collagen